Moreover, primary analyses do not inform on possible mediators of outcome, which can explain treatment mechanisms of action. Thus moderator and mediator analyses are needed to advance our understanding of treatment effects, improve research methodology, and ultimately help develop more effective and targeted interventions (Kazdin, 2001; March and Curry, 1998; Schatzberg and Kraemer, 2000.) .
The term moderator is generally used to describe a variable that, not influenced by treatment, can influence treatment efficacy. In a placebo-controlled clinical trial, "efficacy" is the difference in outcome between active treatment and placebo (Baron and Kenny, 1986; Schatzberg and Kraemer, 2000) . Baseline, prerandomization characteristics, such as age, gender, and illness severity, can function as moderators if they identify patient subgroups with different treatment effect sizes. The effect size expresses the difference between active treatment and control in standard deviation units (Cohen, 1988) . Moderator analyses are "protected" by randomization against biases in treatment assignment and are therefore more informative than mere predictors of outcome. Predictors are pretreatment variables associated with final outcome regardless of treatment assignment and uncontrolled for possible placebo effects or spontaneous improvement. In fact, predictor analyses do not require a controlled clinical trial and can be performed on naturalistically collected databases. The term mediator is generally used to describe variables that change during treatment, are associated with outcome, and can explain mechanisms of action of treatment (Baron and Kenny, 1986, MTA Cooperative Group, 1999) .
Mediator and moderator analyses have important limitations. They are secondary analyses, with lower statistical power than primary analyses, and therefore at substantial risk for false-negative results (type II error). Moreover, because multiple analyses are typically conducted, falsepositive findings (type I error) are also possible. For these reasons, moderator and mediator analyses are exploratory and hypothesis-generating rather than conclusive or hypothesis-testing (Schatzberg and Kraemer, 2000) .
Potential moderators and mediators can be identified on theoretical grounds or on the basis of empirical data from previous studies. Demographic characteristics, such as age, gender, and ethnicity, can be associated with differential treatment response. In fact, development can influence both pharmacokinetics and pharmacodynamics, and consequently medication tolerability and efficacy (Ryan and Varma, 1998; Vitiello and Jensen, 1995) . Treatment response can also vary based on gender (Martenyi et al., 2001) or race/ethnicity (Wood, 1998) . Representation of females and ethnic minorities, and appropriate subgroup analyses, are now a requirement in federally funded research (Freedman et al., 1995; National Institutes of Health, 1994) . Illness characteristics, such as type of disorder, severity, and comorbidity, can also affect treatment response (MTA Cooperative Group, 1999) , as treatment may be less efficacious in more severe forms of illness or comorbid conditions. Child intellectual level can moderate pharmacological effect (Aman et al., 1991) . Family socioeconomic status may influence outcome via possible associations with attitude toward pharmacotherapy, motivation for research participation, expectations, treatment adherence, or accuracy of reporting. Among possible mediators of outcome, treatment adherence is expected to be associated with efficacy, while treatment-emergent adverse events can interfere with treatment and impair efficacy.
The current literature on moderators and mediators of treatment in childhood anxiety disorders is rather limited. A placebo-controlled trial of sertraline in 22 children and adolescents with generalized anxiety disorder found sertraline efficacious for anxiety regardless of comorbid depression , but the small sample size prevents drawing conclusions. In a larger controlled study, comorbidity did not moderate response to cognitive-behavioral therapy in anxious children (Kendall et al., 2001) . Comorbid depression was predictive of poor response to cognitive-behavioral therapy in youths with anxiety disorders (Berman et al., 2000) . Of two studies of selective serotonin reuptake inhibitors (SSRIs) in childhood obsessive-compulsive disorders, one found greater response to fluvoxamine among children than adolescents (Riddle et al., 2001) , while the other found no associations between age, gender, ethnicity, comorbidity, or socioeconomic status and response to sertraline . In depression, no predictors of response to fluoxetine were found in a one study (Kowatch et al., 1999) , while another found that clinical source of referral (compared with advertisement) and more severe hopelessness and cognitive distortion were associated with poor response to cognitive-behavioral therapy (Brent et al., 1998) .
The present analyses were largely exploratory in nature. Two main sets of questions were addressed: 1. Are there suggestions that age, gender, ethnicity, specific anxiety disorder, severity of illness, comorbid disruptive behavior disorders, depressive symptoms, intellectual level, or parent socioeconomic status was associated with treatment outcome in this clinical trial? 2. Are there suggestions that treatment adherence, medication dose, severity of adverse events, or blinded clinician's attribution was associated with treatment outcome in this clinical trial? More specifically, it was predicted that greater baseline severity of illness, presence of comorbid disruptive behavior disorders, lower intellectual level of the patient, and lower family socioeconomic status would be associated with reduced efficacy of fluvoxamine. It was also predicted that better treatment adherence and lower incidence of treatment-emergent adverse events would be associated with greater fluvoxamine efficacy. Because medication dose was adjustable and not fixed, the study was not designed to test dose-effect relationships. However, the association between daily dose received and outcome was examined for heuristic purposes. The association between outcome and end-of-treatment guess by the blinded rater as to which treatment group the patient had been randomized was examined to test the integrity of the study masking.
METHOD

Study Sample and Primary Outcomes
We analyzed the database of a recently reported five-site, 8-week, randomized, double-blind, placebo-controlled clinical trial of fluvoxamine in 128 patients aged 6-17 years suffering from DSM-IV-defined generalized anxiety disorder, social phobia, or separation anxiety disorder, with substantial functional impairment (i.e., a score of less than 60 on the Children's Global Assessment Scale) (RUPP Anxiety Study Group, 2001) . Major depression, mania, psychosis, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder, pervasive developmental disorders, and mental retardation were exclusion criteria. All diagnoses were ascertained on the child and parent Schedule for Affective Disorders and Schizophrenia for School-Age Children (Kaufman et al., 1997) . Fluvoxamine daily dosage ranged from 50 to 250 mg in children and 50 and 300 mg in adolescents, based on clinical response. The study was approved by the institutional review boards at each site and monitored by the NIMH Data and Safety Monitoring Board. Randomization was centralized, computerized, and stratified by site, gender, and age (children versus adolescents). Sample characteristics are provided in Table 1 . The primary outcome measure was the Pediatric Anxiety Rating Scale (PARS) total score, whose interrater reliability was excellent (intraclass correlation = 0.97) (RUPP Anxiety Study Group, 2002) . Severity of illness was measured on the Clinical Global ImpressionSeverity scale (CGI-S) (Guy, 1976) , whose interrater reliability was 0.78. In addition, responder status was defined as an end-of-treatment score of 1 (free of symptoms), 2 (much improved), or 3 (improved) on a modified CGI-Improvement scale (Klein et al., 1992) . Assessments were completed at baseline and each following visit (at weeks 2, 3, 4, 5, 6, and 8) by blinded raters, who were child and adolescent psychiatrists in charge of the patients' clinical management, including evaluation of adverse events and dose adjustments. The rate of premature discontinuation was 16% in the fluvoxamine group and 22% in the placebo group. The primary analysis, an intent-to-treat, mixed-model, randomeffects regression analysis, found a greater decline in PARS total score among the 63 patients randomized to fluvoxamine than among the 65 patients on placebo (p < .001), with no significant site by time by treatment effects. Response rate was 76% for fluvoxamine and 29% for placebo (p < .001) (RUPP Anxiety Study Group, 2001 ).
Potential Moderators
Age. The child group (age 6-12 years) was compared with the adolescent group (age 13-17), consistently with study stratification. Age was also examined as a continuous variable to achieve greater statistical power, with similar results. The analyses on the categorical variables are presented here.
Gender. Gender was also a stratification variable in the study. Race/Ethnicity. Because most of the patients were white and the other racial/ethnic groups were much smaller, race/ethnicity was tested by comparing whites with nonwhites.
Anxiety Disorder. There was considerable comorbidity among the three anxiety disorders (Table 1) . Only 49 patients (38%) had only one anxiety disorder, and 26 (20%) met criteria for all three disorders.
Severity. Patients were classified as "severe" if the baseline score of the CGI-S was 5 ("markedly ill") or greater (6: "severely ill"; 7: "among the most extremely ill patients") (Guy, 1976) . Patients with scores below 5 were classified as "nonsevere."
Comorbidity. ADHD was the most common comorbid disorder. ADHD was not an exclusion criterion unless the child was deemed to be in need of pharmacotherapy for ADHD. No study participant met diagnostic criteria for major depression, which was an exclusion criterion. Depression symptoms were scored at baseline on the Children's Depression Rating Scale-Revised (Poznanski et al., 1985) by the rater based on separate child and parent interviews. Youth (CDRS-Y) and parent (CDRS-P) total scores were examined as possible moderators.
Intellectual Level. The patient's IQ was estimated with the Kaufman Brief Intelligence Test (Kaufman and Kaufman, 1987) .
Family Socioeconomic Status. Both family yearly income and parental highest education level were examined.
The two treatment groups did not differ on any of these variables at baseline (Table 1) .
Potential Mediators
Treatment Adherence. Treatment adherence was measured by total number of days on medication.
Dosage. Dosage was expressed as mean daily dose of fluvoxamine or placebo received by each subject during the study.
Treatment-Emergent Adverse Events. Patients with at least one "moderate" or "severe" adverse event were compared to patients with absent or only "mild" adverse events. During the study, adverse events were recorded independently of possible relationship with treatment and classified into "mild" (not causing functional interference and not requiring medical attention), "moderate" (causing some functional interference and/or requiring medical attention), or "severe" (preventing normal functioning in a usual daily activity of the child and/or requiring medical attention). The most common adverse events were headache, abdominal discomfort, increased motor activity, and difficulty falling asleep (RUPP Anxiety Study Group, 2001) .
Study Blindness. At end of treatment for each patient, the blinded rater was asked to indicate which treatment he/she believed the patient was randomized to. The correctness of this guess and its association to improvement and adverse events were examined.
Statistics
The mixed-model random-effects regression analysis on the PARS total score, with treatment group and site as fixed effect and time on treatment as random effect, was repeated, entering each of the potential moderator or mediator variables (strata) and testing for possible interaction and main effects. The presence of a three-way (strata by treatment by time) interaction effect indicates that the variable influenced outcome by increasing or decreasing the fluvoxamine versus placebo effect size. The presence of a two-way (strata by time) interaction effect indicates that the tested variable influenced efficacy irrespective of treatment assignment, thus functioning as a mere predictor (but not as a moderator) of outcome. Thus, only the presence of a threeway interaction identifies a variable as a moderator or mediator.
Statistical significance of differences between subgroups was set at p < .05 (two-tailed) and tested with the Student t test for continuous measures or χ 2 for categorical outcomes. Inasmuch as these were descriptive, hypothesis-generating analyses, no attempt was made to control for multiple analyses. Statistically significant findings were further explored through analyses of the CGI-defined responder rate. Note: Values represent numbers (n) with percentage in parentheses unless otherwise specified. PARS = Pediatric Anxiety Rating Scale total score; ADHD = attention-deficit/hyperactivity disorder; CDRS-Y = Children's Depression Rating ScaleRevised total score based on youth's report; CDRS-P = CDRS total score based on parent's report. a χ 2 tests are reported for categorical variables; t tests are reported for continuous variables. b Severe: score of 5 ("markedly ill") or greater on the Clinical Global Impression-Severity scale. c Kaufman Brief Intelligence Test. d At least one "moderate" or "severe" treatment-emergent adverse event during the trial.
Because of the limited statistical power, treatment effect sizes were also computed by dividing the difference between group slopes by the pooled standard deviation (Cohen, 1988) , to describe the entity of the observed difference independently of statistical significance. Effect sizes of 0.2 are usually considered small, 0.5 moderate, and 0.8 or greater large (Cohen, 1988) . The presence of a moderate or large effect size, even if not statistically significant, should alert the reader of the possibility of real differences that could not reach significance because of limited statistical power. In fact, the power to declare a three-way interaction effect statistically significant at p < .05 ranged from 51% to 62% for a large effect size (0.8) and from 23% to 29% for a medium effect size (0.5). For two-way interaction effects, however, the power ranged from 98% to 99% for a large effect size and from 70% to 80% for a medium effect size.
RESULTS
Moderator Analyses
Of the 13 variables examined as possible moderators, a significant three-way interaction effect was found only for the depression symptom total score based on parent report (CDRS-P) ( Table 2 ). The superiority of fluvoxamine over placebo was more marked among patients with lower CDRS-P scores. This was due to differential improvement by CDRS-P scores in the placebo group. Patients with lower CSRS-P scores improved less on placebo (mean slope = -0.27) than patients with higher CDRS-P scores (mean slope = -0.62). In the fluvoxamine group, improvement was similar in the CDRS-P subgroups. Consequently, the difference between fluvoxamine and placebo was more marked among patients with lower CDRS-P scores. This interaction was not evident on the depression scores based on child interview (CDRS-Y). Moreover, the CGI-defined improvement rate did not confirm a moderating effect of CDRS-P score. Fluvoxamine response rate was 78.6% among the 28 patients with CDRS-P score >28 and 74.2% among the 31 patients with CDRS-P ≤28, while placebo response rate was 30.3% (n = 10/33) and 25.9% (n = 7/27), respectively (χ 2 1 = 0.10, p = .76). A significant two-way interaction effect was found for the presence of social phobia (SoP), which was associated with lower improvement on the PARS (Table 2 ). In the fluvoxamine group, the CGI-defined response rate was 79% for patients with SoP (n = 39) versus 71% for patients without SoP (n = 24) (χ 2 = 0.06, p = .80). In the placebo group, the response rate was 24% for patients with SoP (n = 45) versus 40% for patients without SoP (n = 20) (χ 2 1 = 0.95, p = .33). A significant two-way interaction effect was also found for severity of illness (Table 2) , as the decline in anxiety symptoms was steeper for more severe patients. In the fluvoxamine group, the CGI-defined response rate was similar among severe (n = 34) and nonsevere patients (n = 18): 76% versus 78%, respectively. In the placebo group, the response rate was 22% among severe (n = 49) versus 50% among nonsevere patients (n = 16) (χ 2 1 = 3.19, p = .07). Inspection of the effect sizes of other variables revealed that only race/ethnicity approached a moderate effect size (0.47) ( Table 2) . Although neither the three-way nor twoway interaction was statistically significant, this variable was further explored because of its effect size. The CGIdefined response rate was 78% among whites (n = 41) and 73% among nonwhites (n = 22) in the fluvoxamine group, and 22% among whites (n = 40) and 40% among nonwhites (n = 25) in the placebo group (χ 2 1 = 1.51, p = .22).
Mediator Analyses
A significant three-way interaction effect was detected for blinded clinician's guess of treatment assignment (Table  3) . For patients receiving fluvoxamine, improvement was associated with rater's correct guess (i.e., attribution to fluvoxamine). For patients receiving placebo, there was an equally strong association between improvement and incorrect guess (i.e., attribution to fluvoxamine). Thus in both treatment groups improvement tended to be attributed to fluvoxamine and lack of improvement to placebo (Table  4) . To assess whether also adverse events influenced rater's guess, guesses for patients who had not improved were examined by severity of adverse events. Of the 29 nonresponders with higher severity of adverse events (i.e., at least one "moderate" adverse event), none was attributed to the fluvoxamine group. Of the 32 nonresponders with low severity of adverse events (i.e., none or only mild events), only 1 was attributed to fluvoxamine.
No significant interaction effects were found for severity of treatment-emergent adverse events or medication mean daily dose. Mean daily dose, though not significant, had a moderate effect size (0.64) ( Table 3) .
DISCUSSION
These secondary analyses of a placebo-controlled trial of fluvoxamine in youths with anxiety disorders examined the possible impact on outcome of certain baseline and treatment-emergent variables. A statistically significant moderating effect of baseline depressive symptoms as measured by the parent-based CDRS-P was found: fluvoxamine efficacy over placebo was more marked in the Note: Boldface value indicates statistical significance, p < .05. SAD = separation anxiety disorder; SP = social phobia; GAD = generalized anxiety disorder; ADHD = attention-deficit/hyperactivity disorder; CDRS-P = Children's Depression Rating Scale-Revised-Parent version, mean + subgroup with lower CDRS-P scores. The interaction was due to less improvement in the lower-depression subgroup than in the higher-depression one in the placebo group. The finding was unexpected and not confirmed by analyses of the child-based CDRS. It is noteworthy that none of the study patients suffered from major depression (an exclusion criterion) and that CDRS scores were below 40, which is the usual threshold for possible depressive disorder (Poznanski et al., 1985) . The clinical significance of the finding is doubtful at this time.
SoP had a statistically significant, but rather modest, effect as predictor of lower degree of improvement. In adults, a lower placebo response has been reported among patients with SoP (7%-24%) than among patients with generalized anxiety disorder (42%-49%) (Allgulander, 1999; Davidson, 2001; Gelenberg et al., 2000; Schneier et al., 1998; Stein et al., 1999; van Vliet et al. 1994) . In the present study, the placebo response rate was 24% among children with SoP and 40% among those with other anxiety disorders, but this difference was not statistically significant.
Severity of illness was a predictor of degree of improvement, regardless of treatment assignment. This is consistent with the fact that patients with more severe baseline symptoms (i.e., greater scores on the PARS) have more "room for improvement" and opportunity for steeper symptom decline over time. There was a trend for more severe patients to be less likely to respond to placebo (22% response rate) than nonsevere patients (50% response rate). This tendency is consistent with reports in adults of an inverse relationship between placebo response and severity of anxious or depressive symptoms (Montgomery, 1998; Paykel et al., 1988; Wilcox et al., 1992) .
Adherence to active medication (but not to placebo!) tended to be accompanied by greater improvement (Table  3 ). The trend is expected, reassures that fluvoxamine was a Effect size calculated by dividing the difference in slopes for the total sample by the pooled standard deviation. b High adverse event group includes patients with at least a "moderate" or "severe" adverse event. Low adverse event group includes patients with only "mild" or no adverse events.
c Blinded clinician's guess of treatment assignment at the end of treatment. Note: Improvement is defined as final Clinical Global Impression-Improvement score of 1 ("free of symptoms"), 2 ("much improved"), or 3 ("improved"). Attribution data were available on 111 of the 128 study subjects (data were not collected on the first 17 subjects who entered the study).
a Binomial test comparing attribution rates to fluvoxamine and to placebo while ignoring uncertain attributions. NS = not significant.
indeed the active ingredient of the study, and confirms that longer exposure to SSRI is accompanied by better outcome. Within the range of doses allowed in the study (50-300 mg/day), no association was found between higher doses and outcome. This is not surprising, as dosage was flexible and clinically adjusted. Under these conditions, the relationship between dose and efficacy is complex and likely to be influenced by various, at times contrasting, elements. In particular, the tendency to increase the dose for nonresponders in an effort to convert them to responder status contributed to the apparently paradoxical finding of higher dosage among nonresponders than among responders (Table 1 ). In general, very little evidence exists for a dose-effect relationship for SSRI medications both in children and adults (Schweizer et al., 2001) .
Analysis of the study blindness, assessed by the rate of correct guesses by blinded clinicians, indicated that the blindness was indeed preserved. If patients improved, raters attributed treatment to active medication (fluvoxamine), and if patients did not improve, the attribution was to placebo, but regardless of the actual treatment assignment (Table 4) . Blinded clinicians who rated the study participants were involved in all aspects of treatment, including adverse events and efficacy assessments at each visit, but the presence of significant adverse events did not seem to influence rater's guess. This finding is consistent with a similar analysis of a clinical trial of fluoxetine in depressed youths (Hughes et al., 2000) .
Limitations
The exploratory, hypothesis-generating nature of moderator and mediator analyses has already been discussed. Analyses were conducted on patient subgroups whose size was frequently rather small, with consequent low statistical power and risk for false-negative findings. This risk was in part mitigated by adopting a p < .05 without adjustments for multiple tests. In addition, effect sizes were computed to provide with an estimate of the entity of the effect, independent of statistical significance. Mediator analyses, contrary to moderator analyses, are not protected by randomization and their interpretation is more challenging than that of moderator analyses. The results are based on the sample characteristics, treatment procedures, and assessment methods (in this case, clinician-rated scales) of this particular clinical trial (RUPP Anxiety Study Group, 2001 ). Extrapolation to current practice must be done with caution and taking into account differences in patients and treatment conditions. Finally, an obvious limitation is that other variables of potential interest, such as duration of illness or referral source, could not be tested because they were not collected.
Clinical Implications
The efficacy of fluvoxamine in the treatment of children and adolescents with generalized anxiety disorder, SoP, or separation anxiety disorder does not seem to be influenced by patient demographics, illness characteristics, or family socioeconomic status. The superiority of fluvoxamine over placebo tends to be more evident among more severe patients (improvement rate of 76% on fluvoxamine versus 22% on placebo) than among less severe patients (improvement rate of 78% on fluvoxamine versus 50% on placebo). Based on these data, the number needed to treat in order to add one improved patient to those who would improve on placebo can be estimated to be 1.8 for the more severe and 3.6 for the less severe patients. The presence of SoP seems to predict lower improvement in anxiety symptoms. Better adherence to active treatment tended to be accompanied by greater improvement.
Conclusions
There are no suggestions that age, gender, ethnicity, specific anxiety disorder, severity of illness, comorbid behavior disorders, intellectual level, parent socioeconomic status, dosage level, or intensity of adverse events affected the main result of the RUPP anxiety study, i.e., that fluvoxamine was highly efficacious in improving children and adolescents with anxiety disorders.
The data provide little empirical support for stratification in clinical trials of antianxiety medications. The presence of SoP, severity of illness, and subsyndromic depressive scores, however, deserves further attention as it may influence placebo response. The study blindness was maintained, in spite of the fact that blinded raters were clinicians involved in all the treatment aspects of the study, including collection of adverse event data.
